http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106220736-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-74 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 |
| filingDate | 2016-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106220736-B |
| titleOfInvention | Chimeric antigen receptor, cell expressing same, preparation method and application thereof |
| abstract | The present invention relates to a chimeric antigen receptor, nucleic acids encoding the same, constructs, expression vectors and transformed cells comprising the nucleic acids, and their pharmaceutical uses. The chimeric antigen receptor of the present invention comprises at least one extracellular domain comprising SC-FV fragments derived from the heavy and light chains of a monoclonal antibody specific for MUC1 or PSCA or genetic alterations based on this domain and optionally a signal peptide, optionally a transmembrane domain, and at least one intracellular signaling domain comprising an immune co-stimulatory signal combination. The capability of the transformed cell of the invention for killing solid tumor cells in vitro and in vivo is obviously enhanced, and is higher than that of the conventional chimeric antigen receptor with a second generation structure. |
| priorityDate | 2016-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 92.